TG Therapeutics Stock Crashes After Briumvi Misses 'Whisper ...

Nov 4, 2024 · For the year, TG Therapeutics now expects $300 million to $305 million in sales of Briumvi. That's up $7.5 million, at the midpoint, from the company's previous outlook.

CouponFollow Extension

$300
OFF

TG Therapeutics Stock Crashes After Briumvi Misses 'Whisper ...

2 days from now

Nov 4, 2024 · For the year, TG Therapeutics now expects $300 million to $305 million in sales of Briumvi. That's up $7.5 million, at the midpoint, from the company's previous outlook.

investors.com

$140
OFF

TG Shares Tumble Following Licensing Deal For MS Drug

2 days from now

Aug 1, 2023 · Terms of the deal hold that TG will receive $140 million upfront, plus an additional $12.5 million upon Briumvi’s launch in the first European Union country. The European …

biopharmadive.com

7%
OFF

TG Therapeutics Stock Rises After Preventing MS Relapses Over …

2 days from now

Sep 18, 2024 · On today's stock market, TG Therapeutics stock rose 0.7%, closing at 25.25, paring back from steeper gains in earlier action. Shares are currently trading at their highest …

investors.com

$43
OFF

TG Therapeutics Price Target Raised To $43 From $30 At JPMorgan

2 days from now

1 day ago · JPMorgan raised the firm’s price target on TG Therapeutics (TGTX) to $43 from $30 and keeps an Overweight rating on the shares. The firm says that with a potential SC Briumvi …

yahoo.com

$650
OFF

TGTX Stock Loses Half Its Value On Briumvi Miss, Deal | Investor's ...

2 days from now

Aug 1, 2023 · TG noted it has the option to buy back the rights to Briumvi under the agreement if TG is acquired. Under the terms of the deal, Neuraxpharm will pay $650 million, including …

investors.com

1%
OFF

TG Therapeutics Stock Breaks Out In Bullish Fashion After 'Solid ...

2 days from now

Aug 19, 2024 · On the stock market today, TG stock surged 14.1% to 25.19. Shares jumped over a buy point at 23.12 out of a new base and a recent high of 22.15, achieved Aug. 7 after the …

investors.com

$83
OFF

TG Therapeutics Reports Third Quarter 2024 Financial Results And …

2 days from now

Nov 4, 2024 · Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, …

businessinsider.com

8%
OFF

New Data For BRIUMVI® (ublituximab-xiiy) Demonstrate That 92

2 days from now

Sep 18, 2024 · After 5 years of continuous BRIUMVI treatment, 8% of patients had Confirmed Disability Progression (CDP) lasting 24 weeks compared to 14.3% of patients who switched …

tgtherapeutics.com

$72
OFF

TG Therapeutics Stock Rockets As Surprise Profit Smashes Views …

2 days from now

Aug 6, 2024 · TG Therapeutics Stock: Briumvi Guidance Raised Briumvi generated $72.6 million in June-quarter sales, handily beating expectations for $65.9 million, according to FactSet. …

investors.com

FAQs about TG Therapeutics Stock Crashes After Briumvi Misses 'Whisper ... Coupon?

How much will TG Therapeutics sell briumvi?

For the year, TG Therapeutics now expects $300 million to $305 million in sales of Briumvi. That's up $7.5 million, at the midpoint, from the company's previous outlook. But in premarket trades on today's stock market, TG Therapeutics stock tumbled 14% to 23.14. ...

How did TG Therapeutics perform in Q3 2024?

Fueled by robust market uptake, TG Therapeutics reported $83.3 million in Q3 2024 U.S. BRIUMVI revenuea 15% increase from the previous quarterand raised its full-year revenue guidance to $300305 million. With over 92% of patients showing no disability progression after five years, BRIUMVI continues to redefine therapeutic benchmarks. ...

Why did TG Therapeutics' Q3 earnings miss EPs expectations?

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed monoclonal antibody for multiple sclerosis, generated $83.3 million in Q3, showing a 15% QoQ growth but a deceleration in revenue growth. ...

Is TG accelerating sales of multiple sclerosis drug briumvi?

However, TG's U.S. sales of multiple sclerosis drug Briumvi are also accelerating. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. ...

Why did T G Therapeutics stock crash Monday?

T G Therapeutics stock crashed Monday — reversing a breakout — after missing third-quarter profit expectations, though sales of its multiple sclerosis treatment beat forecasts. Please watch the video at Investors.com - How To Buy Stocks: Do You Know Your Stock's Personality Type? ...

What happened to TG Therapeutics (tgtx) in Q2?

The drugmaker delivered a couple of surprises in Q2. Shares of TG Therapeutics ( TGTX -7.97%) were crashing 50.4% lower as of 11:12 a.m. ET on Tuesday. The huge sell-off came after the company announced its second-quarter results. Total net product revenue was $16 million in the second quarter. ...